Drug Combination Details
| General Information of the Combination (ID: C49659) | |||||
|---|---|---|---|---|---|
| Name | Triptolide NP Info | + | Cisplatin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Urothelial cancer
[ICD-11: 2C9Z]
|
Investigative | [1] | ||
|
Stomach cancer
[ICD-11: 2B72]
|
Investigative | [2] | |||
|
Pancreatic cancer
[ICD-11: 2C10]
|
Investigative | [3] | |||
|
Bladder cancer
[ICD-11: 2C94]
|
Investigative | [4] | |||
|
Nasopharyngeal cancer
[ICD-11: 2B6B]
|
Investigative | [5] | |||
|
Ovarian cancer
[ICD-11: 2C73]
|
Investigative | [6] | |||
| Click to Show/Hide the Whole Disease Information of This Combination | |||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [6] | |||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | SK-OV-3 | CVCL_0532 | Ovarian serous cystadenocarcinoma | Homo sapiens | ||
| In-vivo Model | Animal model was constructed by injecting PBS containing 500,0000 SKOV3 /DDP cells in the BALB/c-nu nude mouse. | |||||
| Experimental
Result(s) |
Triptolide sensitizes cisplatin-resistant human epithelial ovarian cancer by inhibiting the phosphorylation of AKT. | |||||
| Experiment 2 Reporting the Effect of This Combination | [5] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CASP9 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | MCL1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | HNE-1 | CVCL_0308 | Nasopharyngeal carcinoma | Homo sapiens | ||
| Experimental
Result(s) |
TPL could induce cell apoptosis and synergize with DDP by regulating ROS generation and mitochondrial pathways in HNE1/DDP cells. | |||||
| Experiment 3 Reporting the Effect of This Combination | [2] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | CASP9 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | PARP1 | Molecule Info |
Pathway MAP
|
||
| Biological
Regulation |
Up-regulation | Cytochrome c release | ||||
| In-vitro Model | SC-M1 | CVCL_G299 | Gastric carcinoma | Homo sapiens | ||
| In-vivo Model | SC-M1 cells (5*106 in 100 uL of 0.9% saline) were injected subcutaneously into the hind flank of 6-week-old SCID mice. | |||||
| Experimental
Result(s) |
Synergistic anticancer activity of triptolide combined with cisplatin enhances apoptosis in gastric cancer in vitro and in vivo. | |||||
| Experiment 4 Reporting the Effect of This Combination | [4] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | CASP8 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CASP9 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CCND1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CCNE1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | PARP1 | Molecule Info |
Pathway MAP
|
||
| Biological
Regulation |
Up-regulation | Cytochrome c release | ||||
| In-vitro Model | T24R2 | Bladder carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Triptolide synergistically enhanced the antitumor effect of cisplatin in cisplatin resistant human bladder cancer cells. | |||||
| Experiment 5 Reporting the Effect of This Combination | [3] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | HSP20 | Molecule Info |
Pathway MAP
|
|
| Biological
Regulation |
Up-regulation | Cytochrome c release | ||||
| In-vitro Model | PANC-1 | CVCL_0480 | Pancreatic ductal adenocarcinoma | Homo sapiens | ||
| MIA PaCa-2 | CVCL_0428 | Pancreatic ductal adenocarcinoma | Homo sapiens | |||
| In-vivo Model | To produce a subcutaneous xenograft model, PANC-1 cells (5*106) were injected into the flanks of 6-week-old nude mice. | |||||
| Experimental
Result(s) |
The combined therapy of TPL and DDP triggers a synergic apoptosis via inhibiting HSP27 in human gemcitabine-resistant pancreatic carcinoma and has a strong potential to be developed into a new effective regimen for pancreatic cancer treatment. | |||||
| β. Reversing Drug Resistance by This Combination | ||||||
| Reversing Drug Resistance | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CASP9 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | CDKN1A | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | GSK-3B | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | JNK1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Phosphorylation | JUN | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | TP53 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | RT-112 | CVCL_1670 | Bladder carcinoma | Homo sapiens | ||
| RT-4 | CVCL_0036 | Bladder carcinoma | Homo sapiens | |||
| KK47 | CVCL_8253 | Bladder carcinoma | Homo sapiens | |||
| TCCSUP | CVCL_1738 | Bladder carcinoma | Homo sapiens | |||
| EJ | CVCL_ZC18 | B-cell lymphoma | Homo sapiens | |||
| J82 | CVCL_0359 | Bladder carcinoma | Homo sapiens | |||
| In-vivo Model | To produce a subcutaneous xenograft model, RT112 cells (5*106) were injected into the subcutaneous tissue of pathogen-free 6-week-old BALB/cAJcl-nu/nu mice. | |||||
| Experimental
Result(s) |
Cancer-specific enhancement of CDDP-induced cytotoxicity with triptolide effectively overcome the resistance to a CDDP-based conventional chemotherapy as a treatment for urothelial cancer through an interaction of inactivated glycogen synthase kinase-3beta with p53. | |||||
